转自国资委英文王阿占

Shanghai GeneoDx Biotech Co., LTD of China National Biotec Group Company Limited, a subsidiary of China National Pharmaceutical Group Co., Ltd. (Sinopharm) had produced 6,400 boxes of detection reagent for the nucleic acid of the novel coronavirus by Jan 30, meeting the detection needs of 315,000 people.

Daily supply of the reagent will be enough to test 200,000 people from Feb 1, according to the company.

Sinopharm's affiliated company, Changchun Institute of Biological Products Co., Ltd., urgently produced drugs like antiviral interferon and on Jan 31 delivered the first injections to Wuhan, Central China's Hubei Province where the novel coronavirus first came to light.

It is expected that such interferon will go public in late March and that monthly production will reach one million injections.

Sinopharm's affiliated companies also contributed to blood products used to fight the novel coronavirus epidemic.

Lanzhou Lansheng Plasma-derived Biotherapies Co.,Ltd. of Sinopharm's Beijing Tiantan Biological Products Co., Ltd. sent a van of human immunoglobulin(pH4) to Wuhan on the morning of Jan 28.

In addition to the Lanzhou blood product company, another four blood product enterprises – Chengdu Rongsheng Pharmaceuticals Co., Ltd., Sinopharm Shanghai Plasma-derived Biotherapies Co.,Ltd., Sinopharm Wuhan Plasma-derived Biotherapies Co.,Ltd. and Sinopharm Guizhou Plasma-derived Biotherapies Co.,Ltd. - are also under stable production and have enough blood products in storage.

The companies have also improved monitoring and emergency management on production, quality, storage and delivery to ensure drug supply wherever required.

13683848.jpg

Changchun Institute of Biological Products Co., Ltd. delivers the first antiviral interferon injections to Wuhan, Central China's Hubei Province on Jan 31. [Photo/sasac.gov.cn]